Candriam SCA’s United Therapeutics UTHR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $29.1M | Sell |
53,684
-9,382
| -15% | -$5.28M | 0.13% | 156 |
|
|
2026
Q1 | $37.4M | Sell |
63,066
-64,149
| -50% | -$31.9M | 0.19% | 115 |
|
|
2025
Q4 | $62M | Buy |
127,215
+3,828
| +3% | +$1.78M | 0.31% | 72 |
|
|
2025
Q3 | $51.7M | Buy |
123,387
+40,176
| +48% | +$13.5M | 0.27% | 87 |
|
|
2025
Q2 | $23.9M | Buy |
83,211
+3,998
| +5% | +$1.19M | 0.14% | 144 |
|
|
2025
Q1 | $24.4M | Buy |
79,213
+4,606
| +6% | +$1.58M | 0.15% | 139 |
|
|
2024
Q4 | $26.3M | Buy |
74,607
+7,459
| +11% | +$2.74M | 0.15% | 135 |
|
|
2024
Q3 | $24.1M | Buy |
67,148
+2,635
| +4% | +$890K | 0.14% | 151 |
|
|
2024
Q2 | $20.5M | Buy |
64,513
+61,573
| +2,094% | +$16.3M | 0.12% | 163 |
|
|
2024
Q1 | $675K | Sell |
2,940
-433
| -13% | -$97.7K | ﹤0.01% | 634 |
|
|
2023
Q4 | $742K | Buy |
3,373
+389
| +13% | +$89.7K | 0.01% | 625 |
|
|
2023
Q3 | $674K | Hold |
2,984
| – | – | ﹤0.01% | 601 |
|
|
2023
Q2 | $659K | Sell |
2,984
-4,597
| -61% | -$1.02M | ﹤0.01% | 663 |
|
|
2023
Q1 | $1.56M | Buy |
+7,581
| New | +$1.87M | 0.01% | 627 |
|
|
2018
Q4 | – | Sell |
-2,800
| Closed | -$358K | – | 848 |
|
|
2018
Q3 | $358K | Buy |
+2,800
| New | +$346K | ﹤0.01% | 744 |
|
|
2018
Q2 | – | Sell |
-4,142
| Closed | -$465K | – | 826 |
|
|
2018
Q1 | $465K | Hold |
4,142
| – | – | 0.01% | 685 |
|
|
2017
Q4 | $613K | Buy |
4,142
+1,919
| +86% | +$244K | 0.01% | 648 |
|
|
2017
Q3 | $261K | Sell |
2,223
-1,310
| -37% | -$167K | ﹤0.01% | 703 |
|
|
2017
Q2 | $458K | Sell |
3,533
-10,467
| -75% | -$1.31M | 0.01% | 665 |
|
|
2017
Q1 | $1.9M | Hold |
14,000
| – | – | 0.04% | 456 |
|
|
2016
Q4 | $2.01M | Hold |
14,000
| – | – | 0.05% | 369 |
|
|
2016
Q3 | $1.65M | Hold |
14,000
| – | – | 0.04% | 395 |
|
|
2016
Q2 | $1.48M | Sell |
14,000
-4,000
| -22% | -$446K | 0.04% | 360 |
|
|
2016
Q1 | $2M | Sell |
18,000
-15,100
| -46% | -$1.91M | 0.05% | 322 |
|
|
2015
Q4 | $5.18M | Sell |
33,100
-7,000
| -17% | -$1.02M | 0.14% | 170 |
|
|
2015
Q3 | $5.26M | Sell |
40,100
-3,900
| -9% | -$626K | 0.13% | 193 |
|
|
2015
Q2 | $7.65M | Buy |
44,000
+8,000
| +22% | +$1.44M | 0.16% | 175 |
|
|
2015
Q1 | $6.21M | Buy |
36,000
+7,000
| +24% | +$1.07M | 0.13% | 212 |
|
|
2014
Q4 | $3.75M | Buy |
+29,000
| New | +$3.74M | 0.08% | 282 |
|
Other funds holding UTHR
ACA
JT
Candriam SCA's UTHR Position: Q2 2026 in Review
Candriam SCA reduced its United Therapeutics (UTHR) stake by 15% in Q2 2026, selling an estimated $5.28M and leaving 53,684 shares worth $29.1M. The position accounts for 0.13% of the portfolio, ranked #156.
Candriam SCA first reported a position in UTHR in Q4 2014 and has held it in 29 quarters since. The position peaked at $62M in Q4 2025. 875 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.
- Candriam SCA held 53,684 shares of United Therapeutics worth $29.1M as of Q2 2026.
- Candriam SCA sold 9,382 United Therapeutics shares in Q2 2026, an estimated $5.28M.
- United Therapeutics made up 0.13% of Candriam SCA's portfolio in Q2 2026, its #156 holding.
- Candriam SCA first reported a position in United Therapeutics in Q4 2014 and has held it in 29 quarters since.
- Candriam SCA's United Therapeutics position peaked at $62M in Q4 2025.
- 875 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.
Based on Candriam SCA's 13F filing for Q2 2026, filed 13 Aug 2026.